Cargando…

Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis

Fingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferret-Sena, Véronique, Capela, Carlos, Macedo, Ana, Salgado, António Vasco, Derudas, Bruno, Staels, Bart, Sena, Armando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Molecular Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797671/ https://www.ncbi.nlm.nih.gov/pubmed/36590913 http://dx.doi.org/10.3389/fnmol.2022.1077381

Ejemplares similares

Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2018)

Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
por: Ferret-Sena, Véronique, et al.
Publicado: (2016)

Serum Lipoprotein Profile Is Associated With Protective Effects of Oral Contraceptive Use on Multiple Sclerosis Severity: A Cross-Sectional Study
por: Sena, Armando, et al.
Publicado: (2019)

The CD36-PPARγ Pathway in Metabolic Disorders
por: Maréchal, Loïze, et al.
Publicado: (2018)

Ochratoxin A Induces Steatosis via PPARγ-CD36 Axis
por: Zheng, Qian-Wen, et al.
Publicado: (2021)

PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells
por: Chearwae, W, et al.
Publicado: (2008)

Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours
por: Marques, A R, et al.
Publicado: (2004)

Coordinated Regulation of PPARγ Expression and Activity through Control of Chromatin Structure in Adipogenesis and Obesity
por: Eeckhoute, Jérôme, et al.
Publicado: (2012)

The Peroxisome Proliferator-activated Receptor γ (PPARγ) Controls Natural Protective Mechanisms against Lipid Peroxidation in Amyotrophic Lateral Sclerosis
por: Benedusi, Valeria, et al.
Publicado: (2012)

Altered PPARγ Expression Promotes Myelin-Induced Foam Cell Formation in Macrophages in Multiple Sclerosis
por: Wouters, Elien, et al.
Publicado: (2020)

IP receptor-dependent activation of PPARγ by stable prostacyclin analogues
por: Falcetti, Emilia, et al.
Publicado: (2007)

PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-γ/CD36 Pathway
por: Liu, Yu, et al.
Publicado: (2017)

Porphyromonas gingivalis exacerbates the progression of fatty liver disease via CD36-PPARγ pathway
por: Ahn, Ji-Su, et al.
Publicado: (2021)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

PPAR-γ: Therapeutic Potential for Multiple Sclerosis
por: Drew, Paul D., et al.
Publicado: (2008)

The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPARγ
por: Firmin, François F., et al.
Publicado: (2017)

Nrf2, a PPARγ Alternative Pathway to Promote CD36 Expression on Inflammatory Macrophages: Implication for Malaria
por: Olagnier, David, et al.
Publicado: (2011)

WISP1 alleviates lipid deposition in macrophages via the PPARγ/CD36 pathway in the plaque formation of atherosclerosis
por: Liu, Dian, et al.
Publicado: (2020)

Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients
por: Muls, Nathalie, et al.
Publicado: (2014)

Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis
por: Friess, Jörg, et al.
Publicado: (2017)

Increased Percentage of CD8(+)CD28(−) Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis
por: Houston, Timothy W., et al.
Publicado: (2022)

PPARs/RXRs in Cardiovascular Physiology and Disease
por: Finck, Brian N., et al.
Publicado: (2008)

Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1
por: Jia, Qingling, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor γ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages
por: Chinetti-Gbaguidi, G., et al.
Publicado: (2016)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

High-density Lipoprotein Increases the Uptake of Oxidized Low Density Lipoprotein via PPARγ/CD36 Pathway in Inflammatory Adipocytes
por: Zhong, Qiaoqing, et al.
Publicado: (2015)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

The Modulation of PPARγ1 and PPARγ2 mRNA Expression by Ciglitazone in CD3/CD28-Activated Naïve and Memory CD4+ T Cells
por: Norazmi, Mohd Nor, et al.
Publicado: (2012)

Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism
por: Lizcano, Fernando, et al.
Publicado: (2013)

CD36 – A novel molecular target in the neurovascular unit
por: Ioghen, Octavian, et al.
Publicado: (2021)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
por: Huang, Chiang-Chi, et al.
Publicado: (2021)

The role of CD36-Fabp4-PPARγ in skeletal muscle involves insulin resistance in intrauterine growth retardation mice with catch-up growth
por: Liu, Jing, et al.
Publicado: (2022)

PPARγ in Neuroblastoma
por: Peri, Alessandro, et al.
Publicado: (2008)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1komcu6c142biga045sdtcqhfg